European Union - English - EMA (European Medicines Agency)

sanofi pasteur msd, snc - purified diphtheria toxoid, purified tetanus toxoid, purified pertussis toxoid, purified pertussis filamentous haemagglutinin, hepatitis b surface antigen, inactivated type 1 poliovirus (mahoney), inactivated type 2 poliovirus (mef 1), inactivated type 3 poliovirus (saukett), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - this combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis b caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by haemophilus influenzae type b.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - tetanus toxoid; diphtheria toxoid; pertussis toxoid; filamentous haemagglutinin (fha); pertactin; polio virus type 1 inactivated; polio virus type 2 inactivated; polio virus type 3 inactivated; adsorbed aluminium phosphate; adsorbed fimbriae types 2 + 3 - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-pertussis-poliomyelitis-tetanus

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - diphtheria toxoid; tetanus toxoid; poliovirus, type 1; poliovirus, type 2; poliovirus, type 3 - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - bacterial and viral vaccines, combined; diphtheria-poliomyelitis-tetanus

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - vi polysaccharide of salmonella typhi; hepatitis a virus - solution and suspension for suspension for injection in pre-filled syringe - 160/25 - bacterial and viral vaccines, combined; typhoid-hepatitis a

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid; filamentous haemagglutinin; hepatitis b surface antigen (purified); hib purified capsular polysaccharide bound to tetanus toxoid; pertactin (69 kda omp); pertussis toxoid; poliovirus type 1 (inactivated); poliovirus type 2 (inactivated); poliovirus type 3 (inactivated) - injection - min 30 iu/0.5 ml - diphtheria toxoid min 30 iu/0.5 ml; filamentous haemagglutinin 25 mcg/0.5 ml; hepatitis b surface antigen (purified) 10 mcg/0.5 ml; hib purified capsular polysaccharide bound to tetanus toxoid 10 mcg/0.5 ml; pertactin (69 kda omp) 8 mcg/0.5 ml; pertussis toxoid 25 mcg/0.5 ml; poliovirus type 1 (inactivated) 40 du/0.5 ml; poliovirus type 2 (inactivated) 8 du/0.5 ml; poliovirus type 3 (inactivated) 32 du/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d); filamentous haemagglutinin (fha); hib purified capsular polysaccharide; pertactin (prn or 69kda outer membrane protein); pertussis toxoid (pt); polio virus type 1 (inactivated); polio virus type 2 (inactivated); polio virus type 3 (inactivated); tetanus toxoid (t) - injection - min 30iu/0.5ml - diphtheria toxoid (d) min 30iu/0.5ml; filamentous haemagglutinin (fha) 25mcg/0.5ml; hib purified capsular polysaccharide 10 mcg/0.5 ml; pertactin (prn or 69kda outer membrane protein) 8mcg/0.5ml; pertussis toxoid (pt) 25mcg/0.5ml; polio virus type 1 (inactivated) 40du/0.5ml; polio virus type 2 (inactivated) 8du/0.5ml; polio virus type 3 (inactivated) 32du/0.5ml; tetanus toxoid (t) min 40iu/0.5ml

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (mahoney strain), type 2 (mef-1 strain), type 3 (saukett strain)), hepatitis b surface antigen - hepatitis b; tetanus; immunization; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b and poliomyelitis.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate from haemophilus influenzae type b as prp-ompc, outer membrane protein complex of neisseria meningitidis (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b), adsorbed hepatitis b surface antigen produced in recombinant yeast cells (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaccines - procomvax is indicated for vaccination against invasive disease caused by haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis b virus in infants 6 weeks to 15 months of age.,

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - powder and suspension for suspension for injection - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b for infants between 6 weeks and 36 months of age.